All articles tagged with #argenx
Argenx reported that its anti-CD122 antibody FB102 met its primary endpoint in a Phase 2 celiac disease trial, supporting a move to Phase 3. Simultaneously, the company announced that its blockbuster drug Vyvgart failed a Phase 3 trial for Sjögren’s disease, causing shares to drop 13%.
Argenx announced a $2.2 billion acquisition of Forte Biosciences to obtain FB102, a phase 1b anti-CD122 antibody that showed a 29.6% improvement in facial vitiligo and is set for phase 2 readouts in celiac disease later this year. The deal broadens Argenx’s autoimmune portfolio beyond Vyvgart and supports its Vision 2030 plan to reach 50,000 patients across 10 indications, financed by a strong cash position of about $5.2 billion. Forte shareholders will receive $77 per share.
Immunovant's experimental drug, IMVT-1402, has shown promising results in lowering immunoglobulin G (IgG) levels in healthy adults, indicating its potential to treat various autoimmune conditions. The drug led to dose-dependent reductions in IgG without causing negative effects on LDL cholesterol or serum albumin levels. Immunovant's stock soared to a two-year high following the announcement, while shares of Argenx, a competitor with its drug Vyvgart, slipped. Although Argenx currently has a lead in development across rare diseases, analysts believe Immunovant's drug could have implications for self-administered injections in treating rheumatoid arthritis.
Dutch biotech company Argenx launched a $750 million offering after sharing promising Phase II data for its only approved drug, which is being tested as a treatment for a rare neurological disorder. Investment firm Baillie Gifford Overseas Limited has expressed interest in purchasing up to $200 million in shares as part of the offering. Argenx's shares rose approximately 6% in trading following the announcement.
Belgian drugmaker Argenx announced that its antibody treatment, Vyvgart, significantly delayed the progression of chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune nerve disorder that causes loss of feeling and muscle strength in the arms and legs. In a Phase 3 clinical trial, Vyvgart demonstrated a 61% reduction in the risk of relapse compared to a placebo, achieving the trial's main goal.
Zai Lab and argenx have announced positive topline results from the ADHERE study, which evaluated VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint, demonstrating a significantly lower risk of relapse with VYVGART Hytrulo compared to placebo. The therapy showed a 61% reduction in the risk of relapse and a favorable safety profile. Detailed data from the study will be presented at an upcoming medical meeting. CIDP is a rare autoimmune disease that affects the peripheral nervous system, causing weakness and sensory dysfunction in the limbs.
The FDA has approved a new injectable version of argenx's autoimmune disease drug Vyvgart, marketed as Vyvgart Hytrulo, for people with generalized myasthenia gravis. The condition causes a person's immune system to make antibodies that attack their muscles, making movement, speaking, and swallowing difficult and life-threatening when it impedes breathing. The new version will be available in July.
Genmab, a Danish antibody specialist with a $27 billion market cap, has announced a multi-year research deal with Dutch drugmaker argenx to enter the immunology and inflammation market. The companies will split expenses and potential upside and start researching two undisclosed targets in cancer and immunology, though it could grow to more targets over time. Genmab CEO Jan van de Winkel touts M&A potential as the company expands beyond oncology.